LINDSEY SIMMS: Open Payments
NPI 1518218411 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$534 in 33 payments from 14 companies in 2025. Trend: 2023 $535 · 2024 $701 · 2025 $534
Food & beverage: $534
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $190 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $65 |
| GENZYME CORPORATION | 2 | $42 |
| Madrigal Pharmaceuticals | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 3 | $36 |
| Ardelyx, Inc. | 1 | $33 |
| Janssen Biotech, Inc. | 1 | $21 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $16 |
Products named: SKYRIZI, ENTYVIO, RINVOQ, DUPIXENT, CREON, REZDIFFRA, VOQUEZNA, IBSRELA.
Industry payments across LA — which companies pay providers there.
